Summary  
ECOG-ACRIN Cancer Research Group’s Marketing/Clinical Education and Awareness staff will use approved language/images to help increase awareness of EAF223/GABLE and support accrual efforts. The content below may be shared to the ECOG-ACRIN website, affiliated blogs, and social media channels. Links to these channels are included below. Staff at participating EAF223/GABLE sites may also use this content on their own institutions’ social media channels. This plan contains messaging tailored to patients and caregivers.

ECOG-ACRIN Website  
<https://www.ecog-acrin.org>

ECOG-ACRIN Blogs  
<https://blog-ecog-acrin.org>  
<https://advocacy-ecog-acrin.org>

Social Media Channels  
X/Twitter: <https://twitter.com/eaonc>  
Facebook: <https://www.facebook.com/eaonc/>   
LinkedIn: <https://www.linkedin.com/company/ecog-acrin-cancer-research-group/>  
Instagram: <https://www.instagram.com/ecog_acrin/>

Target Audience(s)  
The brain cancer community, including:

* Patients and survivors
* Caregivers
* Advocates
* Research, education, and advocacy organizations (e.g., Glioblastoma Foundation, GBM Foundation, American Brain Tumor Association, National Brain Tumor Society)

Privacy/Confidentiality Considerations  
ECOG-ACRIN will make every possible effort to protect privacy and confidentiality by:

* Keeping social media post content general in nature and avoiding any specifics related to the trial or patients on the trial
* Refraining from direct engagement with individuals about their eligibility for trials
  + Instead, individuals will be directed to consult with their physician and/or the NCI’s Cancer Information Service
* Monitoring posts daily for inappropriate responses/interactions and flagging or removing as needed

General/Website Messaging

**EAF223/GABLE***Identifying Findings on Brain Scans That Could Help Make Better Predictions about Brain Cancer Progression*

**Why consider participating in this study?**

* Research studies are an important way to test the effectiveness of new therapies and

approaches for treating glioblastoma/brain cancer.

* The usual approach (the care most people get) to treat glioblastoma is surgery, followed by radiation and chemotherapy. The effect of treatment is then monitored by taking pictures of the tumor(s) with magnetic resonance imaging (MRI) over time.
* The purpose of EAF223/GABLE is to find out if different imaging techniques can provide additional and more accurate information than the usual MRI, including identifying earlier how a patient’s cancer is responding during their treatment and follow-up.

**What does this study involve?**

* If you decide to take part in EAF223/GABLE, your surgery must occur within 7 weeks before enrolling in the study.
* Then, you will receive the usual treatment of chemotherapy and radiation, with MRIs over the course of therapy. As part of this study, you will undergo at least two dynamic susceptibility contrast (DSC)-MRI scans. DSC-MRI is a special type of MRI that uses an injectable contrast agent and allows doctors to see how fluids flow through the brain.
  + The DSC-MRI scans will be included as part of the routine MRI scans that you will receive during the usual care for treating glioblastoma. The DSC-MRI will add about five minutes to your scan time. You will not need to return for the DSC-MRI in a separate visit from your routine scans.
  + The DSC-MRI scans will be given after you complete your radiation treatment, about 8 weeks apart from each other.
* If particular changes are noticed on the MRI scans, you will receive an additional scan, called a positron emission tomography (PET) scan. PET scans allow doctors to see changes to tissues and other processes in the body. The PET scan requires an injection of Axumin, which is an agent that is approved by the Food and Drug Administration (FDA) to be used in prostate cancer imaging, but it is not yet approved for use in imaging for glioblastoma.
  + If you are scheduled to receive a PET scan, this will occur in a separate visit from your MRI scans.

A diagram of a patient's recovery

Description automatically generated

* After you finish treatment, your doctor will continue to follow your condition every two months for one year, then every 3 months for a maximum of 6 years.

**Who will take part in this study?**

* A minimum of 220 and a maximum of 440 people with newly diagnosed glioblastoma (who have had surgery) will participate in EAF223/GABLE.
* You can decide to stop taking part in the study at any time, even after you have enrolled.

**What are the costs of taking part in this study?**

* Just as you would if you were getting the usual care for your cancer, you and/or your insurance plan will need to pay for some or all of the costs of medical care you get as part of EAF223/GABLE. This includes paying for the MRIs. Check with your insurance company to find out what they will pay for.
* You/your insurance plan will ***not*** have to pay for exams, tests, and procedures done for research purposes only, or that are covered by the study. Check with your doctor to find out what these might be.
  + You will not have to pay for:
    - The DSC portion of the MRI
    - The PET scan using Axumin (if needed)
* You will not be paid for taking part in this study.

**If you would like to know more**

* About the EAF223/GABLE study, talk with your doctor, or:  
   --Visit www.ecog-acrin.org and search EAF223, then select the link to the EAF223 Home Page.
  + If you are seeking information about the locations where the study is available, scroll down the page to Locations and Contacts and click the + sign.

--Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

• About clinical trials:

--General cancer information: visit the NCI website at www.cancer.gov

--Insurance coverage/paying for cancer treatment: visit www.cancer.gov/clinicaltrials/learningabout/payingfor

• About ECOG-ACRIN:

--Visit www.ecog-acrin.org

--For a list of patient resources and links to patient advocacy groups, visit https://ecog-


acrin.org/patients/resources

Social Media Messaging

|  |  |
| --- | --- |
| **Facebook/LinkedIn** | **X/Twitter** |
| The EAF223/GABLE clinical study is testing different imaging techniques that could help make better predictions about brain cancer progression. Learn more here: https://bit.ly/gable-trial | The EAF223/GABLE clinical study is testing different imaging techniques that could help make better predictions about #BrainCancer progression. Learn more here: https://bit.ly/gable-trial cc: @DukeRadiology, @glioblastf, @gbmfoundation |
| Do you have newly diagnosed glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: https://bit.ly/gable-trial | Do you have newly diagnosed #Glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: https://bit.ly/gable-trial |
| Clinical trial EAF223/GABLE, led by Dr. Daniel Barboriak of @DukeRadiology, aims to help newly diagnosed patients with #Glioblastoma by testing a new treatment approach. Learn more: https://bit.ly/gable-trial | #ClinicalTrial EAF223/GABLE, led by Dr. Daniel Barboriak of @DukeRadiology, aims to help newly diagnosed patients with #Glioblastoma by testing a new treatment approach. Learn more: https://bit.ly/gable-trial |

**Hashtags:** #Glioblastoma #ClinicalTrial #BTSM

Images



****